PATENT / DOCKET NO.: 6643R5 CUSTOMER NO.: 027683

II. <u>Listing of Claims</u>

In compliance with the Revised Amendment Format, the text of all claims under examination is submitted, and the status of each is identified. This listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously Amended-presented)

A compound of the following formula A-3:

$$R_1$$
 O N H O O

A-3

wherein,

R₁ is hydroxyalkyl, substituted or unsubstituted phenylamino, alkoxyalkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, or aminoalkyl.

- 2. (Previously Amended-presented) A compound according to claim 1 wherein the compound is in the form of a pharmaceutically acceptable salt thereof.
- 3. (Original) A compound according to claim 2 wherein said pharmaceutically acceptable salt is hydrochloride salt.
- 4. (Previously Amended-presented) A compound according to claim 1 wherein the compound is in the form of a prodrug thereof.

Claims 5 -6 (Cancelled)

7. (Previously Amended presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the following formula A-3:

PATENT / DOCKET NO.: 6643R5 CUSTOMER NO.: 027683

A-3

wherein,

R₁ is hydroxyalkyl, substituted or unsubstituted phenylamino, alkoxyalkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, or aminoalkyl; and, a pharmaceutically acceptable carrier.

- 8. (Previously Amended presented) A pharmaceutical composition according to claim 7 wherein the compound is in the form of a pharmaceutically acceptable salt thereof.
- 9. (Original) A pharmaceutical composition according to claim 8 wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, sulfate, nitrate, phosphate, sulfonate, formate, tartrate, maleate, malate, citrate, benzoate, salicylate, ascorbate, and mixtures thereof.
- 10. (Original) A pharmaceutical composition according to claim 8 wherein said pharmaceutically acceptable salt is hydrochloride salt.
- 11. (Previously Amended-presented) A pharmaceutical composition according to claim 7 wherein the compound is in the form of a prodrug thereof.
- 12. (Cancelled)
- 13. (Original) A pharmaceutical composition according to claim 7 wherein said compound is micronized and said composition is suitable for administration by injection.
- 14. (Original) A pharmaceutical composition according to Claim 7 wherein said compound is coupled to a soluble polymer.

PATENT / DOCKET NO.: 6643R5 CUSTOMER NO.: 027683

15. (Original) A pharmaceutical composition according to Claim 7 wherein said compound is coupled to a biodegradable polymer.

Claims 16-19 (Cancelled)

20. (Previously Amended-presented) A composition according to claim 7 which comprises from 1 mg to 1000 mg of said compound.

Claims 21-24 (Cancelled)

25. (Previously Amended-presented) A pharmaceutical kit comprising:a therapeutically effective amount of a compound of the following formula A-3:

wherein,

 R_1 is hydroxyalkyl, substituted or unsubstituted phenylamino, alkoxyalkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, or aminoalkyl;

and, instruction for use in treating carcinoma.